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Background: The purpose of patient information leaflets (PILs) is to inform patients about the administration,
precautions and potential side effects of their prescribed medication. Despite European Commission guidelines
aiming at increasing readability and comprehension of PILs little is known about the potential risk information has
on patients. This article explores patients’ reactions and subsequent behavior towards risk information conveyed in PILs
of commonly prescribed drugs by general practitioners (GPs) for the treatment of Type 2 diabetes, hypertension or
hypercholesterolemia; the most frequent cause for consultations in family practices in Germany.
Methods: We conducted six focus groups comprising 35 patients which were recruited in GP practices. Transcripts were
read and coded for themes; categories were created by abstracting data and further refined into a coding framework.
Results: Three interrelated categories are presented: (i) The vast amount of side effects and drug interactions commonly
described in PILs provoke various emotional reactions in patients which (ii) lead to specific patient behavior of which
(iii) consulting the GP for assistance is among the most common. Findings show that current description of potential risk
information caused feelings of fear and anxiety in the reader resulting in undesirable behavioral reactions.
Conclusions: Future PILs need to convey potential risk information in a language that is less frightening while
retaining the information content required to make informed decisions about the prescribed medication. Thus,
during the production process greater emphasis needs to be placed on testing the degree of emotional arousal
provoked in patients when reading risk information to allow them to undertake a benefit-risk-assessment of their
medication that is based on rational rather than emotional (fearful) reactions.
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A patient information leaflet is a technical document in-
cluded in every medicine package to offer written infor-
mation about the medication. Patient information leaflets
(PILs) are provided by the manufacturer following a
standard template consisting of the same types of infor-
mation for every medication. Their main purpose is to
inform patients about their medication regarding its ad-
ministration, precautions and potential side effects. As
required by Article 11 of Directive 2001/83/EC, the
content of PILs ought to be unbiased, evidence-based
and presented in a clear, understandable and well-
readable way to suit laypersons [1].
In 2004, the amended Directive 2004/27/EC demanded
readability and comprehension testing of PILs [2]. The
European Commission issued the “Guideline on the read-
ability of the label and package leaflet of medicinal prod-
ucts for human use”, which provides guidance on how to
produce accessible and understandable package leaflets
[3]. More specifically, the guideline provides advice on the
presentation of the content, design and layout including
guidance on consultations with target patient groups and
a way of undertaking a test of a package leaflet in order to
optimize its usability. Specific recommendations for blind
and partially-sighted patients are also provided. As of
November 2005 the European Commission guideline
led to the introduction of readability user tests to dem-
onstrate the readability and usefulness of the package
leaflet to patients. Such tests became obligatory for
newly authorized medicinal products [3,4].The purpose
of user testing is to achieve legible, clear and easy to
use package leaflets [3]. Member states and the European
Medicines Agency agreed on harmonized Quality Review of
Documents (QRD) templates for package leaflets to ensure
linguistic clarity, consistency and accuracy of PILs [4,5].
Despite substantial regulatory efforts to improve read-
ability and comprehensibility patients to date are still
confronted with long texts written in small font size [6],
non-comprehensible medical terms [7] and poorly pre-
sented statistical information leading to misjudgment of
adverse effects and consequently poor decisions on the
medically prescribed treatment [7,8]. For example, a
German survey found that one quarter of participants
were unnerved by the negative information and stopped
taking their medications after reading about potential side
effects [9]. Similar results were obtained from outside the
European Union where over two-thirds of Australian gen-
eral practitioners (GPs) reported patients refusing to take
their medication because of poorly designed PILs [10].
Non-adherence to prescribed medication regimens ac-
counts for substantial worsening of disease, death and in-
creased health care costs [11,12].
Until now numerous studies have focused on how
PILs could be improved with regard to design [13],readability [14] and understanding of adverse effects [7].
Yet little is known about the way patients react when
reading risk information conveyed in PILs and their
subsequent behavior. This paper reports a subset of
findings derived from a larger qualitative study compo-
nent. Within the scope of this paper we focus on pa-
tients’ reactions to PILs which accompany medications
commonly prescribed by GPs for the treatment of Type
2 diabetes (DM), hypertension (HT) or hypercholester-
olemia (HC). These classes of drugs have been chosen
since they are the most widely prescribed [15] and are
the most frequent cause for consultations in GP prac-
tices in Germany [16].
Methods
Focus groups were chosen because they are the most
appropriate method for different groups of people to
interact in order to gain new knowledge and generate
meaningful suggestions, opinions and feedback [17].
Furthermore, focus groups provide a means of listening
to the perspectives of key stakeholders particularly
when current knowledge about a complex phenomenon
is insufficient and expansion is vital [18]. As compared
to one-to-one interviews, focus groups allow group dy-
namic processes and permit the observation to observe
the extent and nature of participants’ agreement and dis-
agreement regarding the topic under investigation [19].
Recruitment of participants
The study was approved by the research ethics commit-
tee of the University of Witten/Herdecke, North Rhine-
Westphalia, Germany. Out of 43 patients recruited by
their GPs, 35 (9 women) agreed to participate in six
focus groups that were conducted between February and
June 2009. Reasons for refusal to participation (4 women,
4 men) included reduced hearing ability, illness of a
spouse or extended holidays. GPs were used to recruit
participants because they function as gatekeepers in the
German health care system. Prior to conducting the focus
group discussions 13 GP practices which form part of the
universities network of research practices were contacted
in writing and invited to recruit patients for the study.
Seven of those got involved in the recruitment process.
Participating patients were selected by their GPs according
to predefined criteria. Patients were eligible if: (1) they had
been prescribed oral medication for at least one of the
aforementioned conditions and (2) were able to speak and
understand German. Patients’ contact details were for-
warded to the researchers for scheduling the focus groups.
Prior to the focus group discussions, candidates were in-
formed of the goal of the focus group. Gender imbalance
of participating patients may be attributable to the selec-
tion of the GPs. All participants signed informed consent
forms before the focus group and were reassured that
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pant received €40 to cover incidental and travel expenses,
thus ensuring that costs did not affect participation.
Focus groups and generating data
The six focus groups were composed of five to seven pa-
tients [20]. The focus group discussions took place in a
youth center in Herdecke – about 7 miles away from the
university; a central venue convenient to all participants
and a neutral meeting point. Small refreshments were
served to create a relaxed atmosphere. All focus groups
were conducted in German. A focus group discussion
guide was developed using the procedure described by
Kruse [21] and pilot-tested to ensure clarity in wording
of questions. Participants were asked in advance to bring
along PILs of their current medication to stimulate dis-
cussion. Two researchers (ORH, VG) were present at
each focus group; one facilitated the discussion, the
other took detailed notes of the main points of the dis-
cussion. In order to reduce peer-pressure the trained
interviewer – who was not known to the participants –
took on a moderator’s role clarifying that there are no
right or wrong answers. The following broad question
was asked: “You are currently taking tablets and in each
medicine box there is a patient information leaflet. Try
to remember last time your GP prescribed you a new
medication. What did you think about the patientTable 1 Focus group discussion guide
Stimuli
1st Stimulus
“You are currently taking tablets and in each medicine box there is a
patient information leaflet. Try to remember last time your GP prescribed
you a new medication. What did you think about the patient information
leaflet that was enclosed with the medication?”
•
2nd Stimulus
“In your opinion, what should a ‘good’ patient information leaflet look like?” •
•
•
C
3rd Stimulus
“If you were given the opportunity to design a patient information leaflet,
what would you include?”
•
4th Stimulus
“What thoughts/feelings do you have when reading your patient
information leaflet?”
•
in
5th Stimulus
“Are there any parts in your patient information leaflet that you don’t
understand?”
•
o
“If so, which ones are those?” •
in
Finally: Coming to a close
“Is there anything that you would like to add or mention?”information leaflet that was enclosed with the medica-
tion?” Additional more specific questions were asked in
the course of the discussion (see Table 1 for focus group
discussion guide). All focus group discussions were re-
corded digitally and transcribed verbatim. Focus groups
were conducted until theoretical saturation was reached,
i.e. no new themes appeared [22]. Please note that all
quotes used below are translations from German into
English.
Data analysis
Data analysis was carried out parallel to conducting the
focus group discussions. The analysis of the transcribed
focus group discussions was performed by a multidiscip-
linary team consisting of a pharmacist, two GPs, a nurse
researcher and two patient representatives not involved
in the study to mirror the patients’ perspective (analysis
team). None of the coders was affected by any of the
three conditions under discussion in this context. In
order to ensure internal consistency of coding, one team
member assumed overall responsibility for analyzing the
data [23]. The analytic process was guided by thematic
framework analysis [24]. The following analysis proced-
ure was utilized. Firstly, during the familiarization
process all transcripts were read several times to identify
recurring themes or ideas. Secondly, an initial coding
framework was developed by two coders throughPrompts
What do you think is the purpose of a patient information leaflet?
What do you like most about your patient information leaflet?
What is it you like least about your patient information leaflet?
Did you ever have problems with your patient information leaflet?
an you tell me about that?
Are you able to find your bearings in the patient information leaflet?
Please try to remember your thoughts or feelings when reading a patient
formation leaflet and describe them in as much detail as possible.
What kind of support do you need in order to understand the content
f your patient information leaflet?
Do you use any other sources of information apart from the patient
formation leaflet?
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tween them were identified. The third step involved cod-
ing of data according to the initial coding framework
and amendment of the framework. During this process
half of the interview transcripts were read and coded for
themes independently by each coder and then the cod-
ing was undertaken jointly by the entire analysis team to
ensure coherence; a line of action that increases the
credibility of the findings. This process led to the refine-
ment of the coding framework by adding or amending
themes and sub-themes. We then applied this final cod-
ing framework to all interview transcripts. Finally, de-
scriptive and explanatory accounts were developed. The
analysis was carried out using the software package
MAX-QDA to manage the data. In establishing trust-
worthiness, the researchers provided feedback to the
participants to ensure credibility of the data [25]. To this
end, participants were invited to the university to review
and comment on the categories. The majority of themes
were confirmed; minor discrepancies were clarified and
resolved through discussion.
Results
The mean age of participating patients was 64.5 years
with the majority aged 50 or above; their age ranged
from 38 to 79 years. While most participants were of
German origin, three had a migrant background (Turk-
ish, Belgian). Most participants were diagnosed with at
least two of the diseases that rendered them suitable for
inclusion in the study. The mean number of regular
daily tablets to be taken was 6.5 (range: 1 to 21). The
average duration of the focus group discussion was
123 minutes with a range of 96 to 150 minutes. During
the focus groups participants engaged well with the
topic. From the wealth of material that our focus group
discussions have generated the following results will
focus on a specifically selected subset of data pertinent
to patients’ emotional reactions and their subsequent be-
havior caused by PILs. Three categories will be pre-
sented: (i) The vast amount of side effects and drug
interactions described in PILs provoke various emotional
reactions in patients which (ii) lead to specific patient
behaviors of which (iii) consulting the GP for assistance
is among the most common.
Emotional reactions caused by PILs
Possible side effects and drug interactions were among
the most prominent issues discussed across all focus
groups. Several discussions revolved around the general
question of whether side effects should be included in
PILs. The vast majority of participants, however, consid-
ered such information important enough to be included.
Some participants spoke in favor of including only what
they called ‘most severe’, ‘relevant’ or ‘important’ sideeffects without being able to specify these attributes fur-
ther. The majority of participants agreed with the ter-
minology for frequency of occurrence of side effects
suggested by the European Commission Pharmaceuticals
Committee and wanted only ‘very common’ and ‘com-
mon’ side effects to be included. ‘Uncommon’, ‘rare’ and
‘very rare’ side effects were deemed expendable as they
had the potential of upsetting the reader unnecessarily
as the following quote demonstrates.
“Very common” and perhaps even “common”; more
than 1 in 10 users is very common, well, this [side
effect] is going to occur more frequently. Ok, “common”
perhaps as well; this is 1 in 100 users but as far as I’m
concerned “uncommon” side effects no longer need to
be included. And “rare” and “very rare” is merely
upsetting (3/165).
The most frequently reported emotional response trig-
gered by the overall appearance of PILs was “fear”. For
many participants the appearance of PILs was decisive
of whether they were being read. Almost all participants
perceived their current PILs as frightening. Patients
stressed the importance of designing PILs in a way that
they felt encouraged to read them. Especially the side ef-
fects described in current PILs frightened participants
and caused them a great deal of uncertainty about
whether they would be affected by them. Participants
used the notion of “being shocked” to describe their feel-
ings triggered by the vast amount of information con-
tained in PILs and the severity of potential side effects.
In addition, the use of a much too small and difficult to
read font size had a rejecting effect. Some participants
felt literally ill when reading the PIL as the following
quotes illustrate:
If I see all the side effects of the drug I am already ill
(5/346).
Generally, you shouldn’t read the side effects otherwise
you might think you are already dead (4/33).
Response behaviors triggered by current PILs
During the focus group discussions participants de-
scribed numerous behaviors which were provoked when
reading PILs: (1) they stopped reading the leaflet; (2)
they glanced through the leaflet; (3) they discarded the
leaflet; (4) they accessed additional information from al-
ternative sources; (5) they sought support from other
professional and lay sources; (6) they stopped taking the
medication or (7) altered the prescribed dosage without
consulting the GP.
Within this key category the two most frequently men-
tioned response behaviors were: ‘seeking support’ and
‘stopping the medication’. With regard to the former,
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members or friends. This was particularly true for those
with a migration background whose command of the
German language was perceived as being insufficient.
Participants said they were thankful for a knowledgeable
person who could explain the content of the PIL in plain
language. Accessing additional information from alterna-
tive sources such as consulting a medical dictionary or
the internet was a frequently employed strategy for clari-
fication. Some participants reached the decision of
whether or how to take the medication based on such
sources.
Another frequently reported response behavior was
taking a break from the prescribed medication. In five
out of six focus groups participants reported on discon-
tinuing their medication after reading PILs. The often
lengthy and incomprehensible description of possible
side effects was a major reason for this decision. In all
but one focus group it was mentioned that the huge
amount of potential side effects would outweigh the
benefits of the medication and therefore patients did not
take their drugs or reduced the dosage without consult-
ing their GPs. The following quotes get to the point of
this:
If you read the entire thing [PIL], you would not want
to take the tablets anyway (1/147).
My wife says: “I’m getting anxious [when reading the
PIL], I don’t take the tablets.” And I say to her: “Just
throw the patient information leaflet away and take
the tablets” (2/317).
Yet another commonly reported response was contact-
ing the GP or less often the pharmacist. Both profes-
sional groups were considered to be in a position to
provide advice regarding the prescribed drug. Although
participants expressed a strong desire to receive custom-
ized information from their GP, they did not necessarily
consult them at times because they thought that their
GP was too busy. Instead pharmacists would be sought
out for assistance. However, it was attested that GPs
were the ones who had an overview of all the medica-
tions a patient was taking. Even if PILs were well written
and easy to comprehend they could never substitute for
a GP’s individual judgment; PILs were generally seen as
less helpful than face-to-face advice.
The patient-physician relationship
Since PILs were not considered as being able to take the
place of a GP’s individual judgment, participants had
much confidence in their GPs and believed that they
were best positioned to know what was good for them.
Thus, participants were convinced that tailored informationregarding the medication and its undesirable side ef-
fects was best provided by their GPs. Some participants
wished that GPs would explain in plain language the
medical terminology used in PILs as the quote below
highlights. Participants also felt it is vital to have a
follow-up appointment when a new medication was
prescribed to see if it had the desired effect. Consulting
the GP became even more important if side effects oc-
curred; a situation in which a leaflet is regarded as not
being useful.
All these medical terms which patients don’t
understand anyway. Each time [I read the PIL] I need a
GP as mediator who explains everything to me (6/298).
Despite the above, participants mentioned that GPs
would sometimes prescribe medication without provid-
ing any instructions on how to take the medication. Yet
GPs were considered as crucial mediators between the
information contained in PILs and their patients. Some
participants mentioned that after the prescription of a
new drug they were more likely to adhere to it but more
reluctant to read the PIL. For participants with a migra-
tion background insufficient knowledge of the German
language prevented them from reading PILs. Instead,
they relied heavily on their GPs to make sense of the in-
formation irrespective of the quality of the PIL.
Participants were well aware that some medications
should not be combined with others or that the efficacy
of a drug could be altered when given in combination
with others. Participants trusted their GPs in communi-
cating this relevant information to them. Yet they also
criticized that their GPs did not have the time for it or
forgot to discuss possible drug interactions. Because of
this, participants thought that drug interactions should
be included in PILs to provide users with the opportun-
ity to look them up for themselves in order to make in-
formed decisions regarding their prescribed medication.
Discussion
The findings of our focus groups showed that PILs –
despite European Commission guidelines and those of
other legislative bodies – still have considerable need for
(linguistic) improvements. It has been demonstrated that
PILs included in medicine prescribed for the treatment
of Type 2 diabetes, hypertension or hypercholesterol-
emia have a deterrent effect on patients. PILs contained
too much risk information which was conveyed in a way
that led to reduced patient compliance. Instead of PILs
contributing to providing a sense of security or reassur-
ance for patients, they provoked negative emotions
which – among other reactions – led participants to dis-
continuing their medication or altering the dosage with-
out prior consultation of their GPs.
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of potential side effects and drug interactions caused nega-
tive emotions which led to undesirable patient reactions.
This finding is similar to Nink & Schröder [9] who found
that 29% of study participants felt insecure when reading
PILs. Insecurity towards PILs increased further with ad-
vancing age affecting almost 37% of participants aged 60
and above. Similarly, investigations undertaken by Koo
et al. [26] and Lee et al. [27] found that PILs were consid-
ered incomprehensible and frightening. Major contribut-
ing factors limiting the usefulness of PILs related to their
length, legibility, readability, design, comprehensibility
and content [27,28,14,29]. Another study analyzing 50
PILs of frequently prescribed medications reported that
only very few manufacturers complied with current
European guidelines; 40% gave no indication of the
likelihood of adverse effects occurring [7]. While the
quality of PILs could be improved by considering key
linguistic features [30] it has been said that complex
organizational politics, goal conflicts and various other
pressures involved in creating PILs adversely affect the
comprehensibility of the texts for patients [31].
The focus groups also revealed that PILs provoked
certain behaviors in patients including accessing infor-
mation from alternative sources or seeking support from
professional and lay persons. Similar patient behavior
has been reported by Lee et al. [27] where many study
respondents were dissatisfied with the quality of the PILs
but only a minority sought information from profes-
sional and lay sources. Although only a few patients
searched the internet or consulted reference books for
pharmaceutical information, such sources were regarded
as vital alternatives. The study undertaken by Vander
Stichele et al. [32] investigating attitudes of physicians
towards PILs for patients revealed that 92% of physicians
thought that such overt information seeking behavior is
limited to a minority of patients and not a general fea-
ture of their behavior. In this context it is important to
note that risk information on pharmaceutical and third
party websites is often incomplete or chaotic due to the
absence of quality control mechanisms [33] leaving pa-
tients ill-informed or even misinformed about known
adverse effects [34] and contraindications [35].
There was a strong emphasis in the focus groups that
GPs were considered the best source and enjoyed partic-
ipants’ trust in providing general drug information as
well as patient-tailored knowledge about side effects and
drug interactions. Even pharmacists were not accepted
as an equally competent source of delivering this infor-
mation. Similar results have been obtained by Lee et al.
[27] where GPs trusted unquestioningly and were
regarded as the primary provider of information about
prescribed medications, followed by community phar-
macists. This is contrary to the findings by Nair et al.[36] who found that most patients consider pharmacists
as the primary source of information since access was
the main factor in determining from whom information
was sought. It is important to note that the majority of
respondents in our study preferred a more passive role
in the decision making process in the sense that respon-
dents expressed a greater preference for their GPs to
make all or most decisions. Despite evidence suggesting
that active patient involvement in medical decision mak-
ing may result in increased treatment adherence and im-
proved outcomes [37], research on patient and provider
characteristics associated with patient decision-making
role preferences found that patients receiving lower
levels of provider communication about decision making
as well as patients being very satisfied with their care are
more likely to prefer provider-made decisions [38]. Al-
though GPs enjoyed a high degree of patients’ trust, on a
daily basis they fell short of their expectations since they
often provided minimal or no instructions when pre-
scribing medication. Thus patients were left to their own
devices to seek for information from sources that are
more readily available then GPs; however, at times these
were less reliable sources such as the internet [33].
Due to the fact that the focus groups were conducted
in a German setting and participants made reference to
PILs published in German, the transferability of the re-
sults presented in this study could be limited and they
deserve further investigation. Besides, the various re-
sponse behaviors described above were triggered in rela-
tion to PILs taken from medication commonly prescribed
for the treatment of Type 2 diabetes, hypertension and
hypercholesterolemia. Therefore it remains unclear what
emotional reactions patients would have described if they
were provided with PILs for other medications. Further-
more, the data of our study have been generated from a
predominantly male sample aged 50 and above which
could have influenced our findings. However, our study
sample appears to be a typical representation of patients
with Type 2 diabetes, hypertension and hypercholesterol-
emia who present at GP practices. Finally, although there
were three patients involved in the focus groups with a
migrant background, it was not our intention to look for
differences between migrants and non-migrants.
Conclusions
The findings of our qualitative study have shown that
current PILs convey risk information in a way that pro-
voked feelings of fear and anxiety in the reader. Such
negative emotions cause patients to make alterations to
their prescribed treatment regimen without prior con-
sultation of their GPs. The raison d’être of PILs is to in-
form patients about application and risks of the prescribed
medication in a clear, understandable and readily readable
way. Yet, our results suggest that reading PILs is associated
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designing future PILs is to develop presentations which
allow the conveyance of risk information in a way that is
perceived as less frightening by patients but will still pro-
vide vital information necessary to make an informed deci-
sion on whether or not to take the prescribed medication.
An informed decision not to take a specific medicine is an
acceptable outcome. From the patients’ point of view,
spoken information provided by their GPs is preferred to
reading PILs. This holds true especially for the conveyance
of risk information. The quality and the extent of the
patient-physician relationship may also contribute to calm-
ing down frightened patients. Yet physicians are also en-
couraged to welcome patients who make use of written
information in order to evoke questions that can be dis-
cussed during consultation with their GPs.
To improve PILs further it is suggested that regulators
and producers of such written information consider
greater involvement of target patient groups at all stages
of the production process. More precisely, during the
production process specific emphasis should be placed
on testing the degree of emotional arousal provoked in
patients when reading certain risk information. Future
generations of PILs should aim at providing information
about possible side effects and drug interactions in a
language of risk that is causing less anxiety in order to
diminish or – if at all possible – avoid typical “knee-jerk
reactions” such as altering the dosage or discontinuing
the prescribed medication. This is vital because Hartley
& Phelps ([39]; p.8) conclude from their review on the
relationship between anxiety and decision-making that:
“anxiety increases the attention to negative choice
options, the likelihood that ambiguous options will be
interpreted negatively and the tendency to avoid
potential negative outcomes even at the cost of
missing potential gains.”
In order to improve the outcome of a benefit-risk-
assessment of a medication the European Commission
should consider including emotional arousal testing as
an additional aspect in the guideline on how to produce
package leaflets.
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